Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 375 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: High Risk Prostate Carcinoma Clear all
Recruiting Phase 2 Interventional

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

NCT05806515
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Surgical Procedure
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
133
States / cities
Anchorage, Alaska • Phoenix, Arizona • Arroyo Grande, California + 96 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 30, 2026, 6:04 AM EDT
Terminated Not applicable Interventional Results available

Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine

NCT01654068
View directory record Official record
Conditions
Vertebral Metastasis
Interventions
Conformal High Dose Intensity Modulated Radiation Therapy
Radiation
Lead sponsor
Ronald McGarry
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Sep 30, 2026, 6:04 AM EDT
Recruiting Phase 1 Interventional

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

NCT06130995
View directory record Official record
Conditions
Androgen Deprivation Therapy, Locally Advanced Prostate Cancer
Interventions
Relugolix and Enzalutamide
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 30, 2026, 6:04 AM EDT
Active, not recruiting Not applicable Interventional

Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer

NCT05958082
View directory record Official record
Conditions
Prostate Cancer
Interventions
Educational video
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Sep 30, 2026, 6:04 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT01368588
View directory record Official record
Conditions
Prostate Cancer
Interventions
three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
2,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
454
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Sep 30, 2026, 6:04 AM EDT
Completed Phase 1 Interventional

C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer

NCT00804245
View directory record Official record
Conditions
Prostate Cancer
Interventions
needle biopsy, PET-CT scans supplemented with 11C-Choline tracer
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
30 Years to 120 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Sep 30, 2026, 6:04 AM EDT
Completed Not applicable Interventional Results available

CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

NCT01985828
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
CyberKnife, Androgen Deprivation Therapy (ADT), Intensity Modulated radiation therapy (IMRT)
Radiation · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 30, 2026, 6:04 AM EDT
Recruiting Early Phase 1 Interventional

A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer

NCT06888102
View directory record Official record
Conditions
High-risk Prostate Cancer
Interventions
Neoadjuvant Epigenetic Therapy
Drug
Lead sponsor
Edwin Posadas, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 30, 2026, 6:04 AM EDT
Active, not recruiting Not applicable Interventional Results available

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

NCT01342367
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bicalutamide, Dutasteride, Finasteride, Radiation
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 30, 2026, 6:04 AM EDT
Active, not recruiting Phase 2 Interventional

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

NCT00329043
View directory record Official record
Conditions
Prostate Cancer
Interventions
LHRH Agonist, Sunitinib Malate, Radical Prostatectomy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Sep 30, 2026, 6:04 AM EDT
Active, not recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

NCT03976843
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
New Orleans, Louisiana • Baltimore, Maryland • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 30, 2026, 6:04 AM EDT
Active, not recruiting Phase 2 Interventional

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

NCT03181867
View directory record Official record
Conditions
Prostate Neoplasms, Prostatic Cancer, Prostate Cancer, Cancer Of Prostate, Metastatic Prostate Cancer
Interventions
18F-DCFPyL, 18F-FDG, PSMA-11
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 30, 2026, 6:04 AM EDT
Completed Phase 2 Interventional

Doxercalciferol Before Surgery in Treating Localized Prostate Cancer

NCT00022412
View directory record Official record
Conditions
Prostate Cancer
Interventions
doxercalciferol, conventional surgery
Dietary Supplement · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 120 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
6
States / cities
Iowa City, Iowa • Rochester, New York • Madison, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Sep 30, 2026, 6:04 AM EDT
Completed Phase 1 Interventional

BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets

NCT00872157
View directory record Official record
Conditions
Prostate Cancer
Interventions
BMTP-11
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Sep 30, 2026, 6:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

NCT07262619
View directory record Official record
Conditions
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions
EIK1005, pembrolizumab (KEYTRUDA® )
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Doral, Florida • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 30, 2026, 6:04 AM EDT
Terminated Phase 1 Interventional Results available

Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

NCT01642732
View directory record Official record
Conditions
Prostate Cancer
Interventions
Everolimus, lupron, bicalutamide, and radiation
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 30, 2026, 6:04 AM EDT
Completed Phase 1Phase 2 Interventional

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

NCT02649790
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
Interventions
KPT-8602, ASTX727, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
26
States / cities
Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 30, 2026, 6:04 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

NCT00860158
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dasatinib, Leuprolide Acetate (LHRH Analogue), Radical Prostatectomy
Drug · Procedure
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Scottsdale, Arizona • Gainesville, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Sep 30, 2026, 6:04 AM EDT
Completed Phase 2 Interventional Results available

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

NCT04523207
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, ADT, Relugolix
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
32
States / cities
Tucson, Arizona • Little Rock, Arkansas • Sherman Oaks, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 30, 2026, 6:04 AM EDT
Completed Not applicable Interventional

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

NCT02346253
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Internal Radiation Therapy, Bicalutamide, Leuprolide Acetate, Goserelin Acetate, Triptorelin Pamoate, Degarelix, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Radiation · Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
Male only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Sep 30, 2026, 6:04 AM EDT
Recruiting No phase listed Observational

HIFU for Focal Ablation of Prostate Tissue: An Observational Study

NCT03620786
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sonablate HIFU device
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
100 participants
Timeline
2018 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 30, 2026, 6:04 AM EDT
Recruiting Phase 2 Interventional

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

NCT04812366
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab, Docetaxel, Niraparib 100mg Oral Capsule, Atezolizumab, Tazemetostat Pill, Capivasertib
Drug
Lead sponsor
University of British Columbia
Other
Eligibility
18 Years and older · Male only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Sacramento, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Sep 30, 2026, 6:04 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

NCT00466752
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
sorafenib tosylate, microarray analysis, immunohistochemistry staining method, gene expression analysis, needle biopsy, therapeutic conventional surgery, laboratory biomarker analysis, western blotting, RNA analysis
Drug · Genetic · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Sep 30, 2026, 6:04 AM EDT
Active, not recruiting Phase 3 Interventional

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NCT05050084
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
Drug · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
567
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 30, 2026, 6:04 AM EDT